Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
67 Leser
Artikel bewerten:
(0)

Global Cell Culture Instruments and Consumables Market 2017-2022 - Rising Demand for Cell Based Therapies

DUBLIN, October 11, 2017 /PRNewswire/ --

The "Cell Culture Instruments and Consumables Market - Global Opportunity Analysis And Industry Forecasts to 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

Global Cell Culture Market is expected to reach USD 21,058 million by 2022, at a CAGR of 10.7% during the forecast period of 2017 to 2022

The global cell culture market is mainly driven by the increase in the life science research, advancement in cell based technology, increasing prevalence of chronic diseases, rising demand for cell based therapies, and increasing cell based production. However, lack of awareness about emerging diagnosis technologies, high cost of cell culture research, and high risk of contamination inhibits the growth of the market to some extent. Moreover, handling and optimization of cell based protocol further challenges the growth of this market.

The large share of this region is primarily attributed to the increased funding in medical research, drug development regulations which demand cell culture products, growing aging population and thereby prevalence of various chronic diseases, and direct & indirect financial investments in the pharma biotech industries.

However, Asia-Pacific region possesses lucrative growth potential for the cell culture market during the forecast period, owing to the increasing demand in China and India, high population zone, various technological advancements, increasing investment in the healthcare and pharmaceutical sector, rising investment from government & non-government bodies, and growing pharma biotech industry in the region.

Market Dynamics

Drivers

  • Increasing Life Science Research
  • Advancement in Cell Based Technology
  • Increasing Prevalence of Chronic Diseases
  • Rising Demand for Cell Based Therapies
  • Increase in Cell Based Vaccine Production

Restraints

  • High Cost of Cell Culture Research
  • High Risk of Contamination

Challenge

  • Handling and Optimization of Protocol for in Vitro Study

Trend

  • Transition from Animal Based Diagnosis to in Vitro Cell Based Diagnosis

Key Topics Covered:

1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation

3. Executive Summary

4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Life Science Research
4.2.2. Advancement in Cell Based Technology
4.2.3. Increasing Prevalence of Chronic Diseases
4.2.4. Rising Demand for Cell Based Therapies
4.2.5. Increase in Cell Based Vaccine Production
4.3. Restraints
4.3.1. High Cost of Cell Culture Research
4.3.2. High Risk of Contamination
4.4. Challenge
4.4.1. Handling and Optimization of Protocol for in Vitro Study
4.5. Trend
4.5.1. Transition from Animal Based Diagnosis to in Vitro Cell Based Diagnosis

5. Cell Culture Market Size, by Product
5.1. Introduction
5.2. Consumables
5.2.1. Media
5.2.1.1. Classical Media and Salts
5.2.1.2. Natural Media
5.2.1.2.1. Coagulants
5.2.1.2.2. Tissue Extracts
5.2.1.2.3. Biological Fluids
5.2.1.3. Synthetic Media
5.2.1.3.1. Serum Containing Media
5.2.1.3.2. Serum Free Media
5.2.1.3.3. Xeno Free Media
5.2.1.3.4. Protein Free Media
5.2.1.3.5. Chemically Defined Media
5.2.1.4. Specialty Media
5.2.1.5. Stem Cell Media
5.2.2. Sera
5.2.2.1. Fetal Bovine Serum
5.2.2.2. New Born Calf Serum
5.2.2.3. Other Animal Sera
5.2.3. Reagents
5.2.3.1. Antibiotics
5.2.3.2. Attached and Matrix Factors
5.2.3.3. Buffers
5.2.3.4. Subculturing Reagents
5.2.3.5. Cryopreservatives
5.2.3.6. Amino Acids
5.2.3.7. Growth Factors and Cytokines
5.2.3.8. Protease Inhibitors
5.2.3.9. Balanced Salt Solutions
5.2.3.10 Others
5.3. Instruments
5.3.1. Cell Culture Vessels
5.3.1.1. Culture Bags
5.3.1.2. Culture Plates
5.3.1.3. T-Flask
5.3.1.4. Culture Dishes
5.3.1.5. Roller Bottles
5.3.2. Bioreactors
5.3.3. Biosafety Cabinets
5.3.4. Carbon Dioxide Incubators
5.3.5. Centrifuges
5.3.6. Microscopes
5.3.7. Cell Counters
5.3.8. Cryopreservative Tanks
5.3.9. Sterilizers
5.3.10. Pipetting Instruments

6. Cell Culture Market Size, by Application
6.1. Introduction
6.2. Toxicity Testing
6.3. Cancer Research
6.4. Drug Discovery and Development
6.5. Regenerative Medicines
6.6. Vaccination
6.7. Recombinant Products
6.8. Stem Cell Technology
6.9. Others

7. Cell Culture Market Size, by End-User
7.1. Introduction
7.2. Pharmaceutical and Biotechnology Industry
7.3. Academic Institutes
7.4. Research Centers

8. Cell Culture Market Size, by Geography

9. Competitive Landscape
9.1. Introduction
9.2. Partnership and Collaborations
9.3. Mergers and Acquisitions
9.4. New Product Launches and Upgradations
9.5. Expansions

10. Company Profiles

  • Agilent Technologies (U.S.)
  • American Type Culture Collection (ATCC) (U.S.)
  • Becton Dickinson (BD) (U.S.)
  • Cell Culture Company (CCC) LLC (U.S.)
  • CellGenix GmbH (Germany)
  • Corning Incorporation (U.S.)
  • GE Healthcare (U.S.)
  • HiMedia Laboratories (India)
  • Incorporation (U.S.)
  • InvivoGen (U.S.)
  • Irvine Scientific (U.S.)
  • Lonza (Switzerland)
  • Merck & Co.
  • PromoCell GmbH (Germany)
  • Sera Care Life Sciences Incorporation (U.S.)
  • Thermo Fisher Scientific (U.S.)

For more information about this report visit https://www.researchandmarkets.com/research/j9hmbt/cell_culture

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.